Steven A Rubin

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. pmc Recent mumps outbreaks in vaccinated populations: no evidence of immune escape
    Steven A Rubin
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA
    J Virol 86:615-20. 2012
  2. doi Neurovirulence safety testing of mumps vaccines--historical perspective and current status
    S A Rubin
    Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 29:2850-5. 2011
  3. doi Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak
    Steven A Rubin
    Division of Viral Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Infect Dis 198:508-15. 2008
  4. doi Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence
    Christian J Sauder
    DVP Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 27:5822-9. 2009
  5. pmc Gene-specific contributions to mumps virus neurovirulence and neuroattenuation
    Christian J Sauder
    United States Food and Drug Administration, CBER, OVRR, DVP, 8800 Rockville Pike, Building 29A, HFM 460, Room 2C20, Bethesda, MD 20892, USA
    J Virol 85:7059-69. 2011
  6. pmc A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines
    Cheryl X Zhang
    FDA, Division of Viral Products, Lincoln Drive, Bethesda, MD 20892, USA
    Biologicals 38:278-83. 2010
  7. ncbi Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity
    Christian J Sauder
    DVP Office of Vaccines Research and Review, Center for Biologics, Evaluation and Research, Food and Drug Administration, Building 29A, Room 1A 21, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Virology 350:48-57. 2006
  8. doi Genetic contributions to influenza virus attenuation in the rat brain
    Li Qi
    CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Neurovirol 14:136-42. 2008
  9. ncbi Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain
    Tahir Malik
    DVP Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Gen Virol 88:2533-41. 2007
  10. ncbi The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study
    Steven A Rubin
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Adminstration, Bethesda, Maryland 20892, USA
    J Infect Dis 191:1123-8. 2005

Collaborators

Detail Information

Publications13

  1. pmc Recent mumps outbreaks in vaccinated populations: no evidence of immune escape
    Steven A Rubin
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA
    J Virol 86:615-20. 2012
    ..Although the geometric mean neutralizing antibody titer of the sera was lower against some virus strains than others, all viruses were readily neutralized, arguing against immune escape...
  2. doi Neurovirulence safety testing of mumps vaccines--historical perspective and current status
    S A Rubin
    Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 29:2850-5. 2011
    ..This review summarizes the current status of mumps vaccine neurovirulence safety testing and insights into models currently approved and those under development...
  3. doi Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak
    Steven A Rubin
    Division of Viral Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Infect Dis 198:508-15. 2008
    ....
  4. doi Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence
    Christian J Sauder
    DVP Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 27:5822-9. 2009
    ....
  5. pmc Gene-specific contributions to mumps virus neurovirulence and neuroattenuation
    Christian J Sauder
    United States Food and Drug Administration, CBER, OVRR, DVP, 8800 Rockville Pike, Building 29A, HFM 460, Room 2C20, Bethesda, MD 20892, USA
    J Virol 85:7059-69. 2011
    ....
  6. pmc A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines
    Cheryl X Zhang
    FDA, Division of Viral Products, Lincoln Drive, Bethesda, MD 20892, USA
    Biologicals 38:278-83. 2010
    ..Our data indicate that testing of 10-100 pfu of virus in mice following intracranial inoculation reliably assesses the virus's neurovirulence potential for humans...
  7. ncbi Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity
    Christian J Sauder
    DVP Office of Vaccines Research and Review, Center for Biologics, Evaluation and Research, Food and Drug Administration, Building 29A, Room 1A 21, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Virology 350:48-57. 2006
    ....
  8. doi Genetic contributions to influenza virus attenuation in the rat brain
    Li Qi
    CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Neurovirol 14:136-42. 2008
    ..Further in vivo and in vitro examination of these five mutations, both individually and in combination, will likely provide important information on the role of specific virus genes in virulence and pathogenesis...
  9. ncbi Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain
    Tahir Malik
    DVP Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Gen Virol 88:2533-41. 2007
    ..These data suggest a polygenic component (i.e. specific and inter-related roles of these amino acid changes) to MuV neuroattenuation...
  10. ncbi The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study
    Steven A Rubin
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Adminstration, Bethesda, Maryland 20892, USA
    J Infect Dis 191:1123-8. 2005
    ..Results indicate that the assay correctly assesses the neurovirulence potential of mumps viruses in humans and is robust and reproducible...
  11. ncbi Mouse neurotoxicity test for vaccinia-based smallpox vaccines
    Zhongqi Li
    Laboratory of Pediatric and Respiratory Viral Diseases, OD Center for Biologics Evaluation and Research, Food and Drug Administration, HFM 460, Bldg 29B, Room 5NN22, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Vaccine 22:1486-93. 2004
    ..With further validation, this assay incorporating a licensed vaccine reference standard and positive control strain may provide important pre-clinical neurotoxicity data on new vaccinia-based smallpox vaccine strains...
  12. pmc Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype
    Steven A Rubin
    DVP Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 77:11616-24. 2003
    ..The potential role of these amino acid changes in neurotropism, neurovirulence, and neuroattenuation is discussed...
  13. pmc Enhanced neurovirulence of borna disease virus variants associated with nucleotide changes in the glycoprotein and L polymerase genes
    Yoshii Nishino
    Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Virol 76:8650-8. 2002
    ..These results suggest that small numbers of genomic differences between BDV variants in the G protein and/or L polymerase can contribute to the variability in BD outcomes...